online course
The most comprehensive review course in internal medicine
Watch online anytime, anywhere
Get up to 22 CME credits through November 11, 2024 for €200
This online course is for:
- General internists
- Subspecialists
- Hospitalists
- Family physicians
- Residents
- Fellows in training specializing in internal medicine
- Medical students
Up to 22 CME credits
22.0 European CME credits (ECMEC®s) that can be converted to AMA credits and are recognized worldwide
On-demand access to video recordings
Review the content at your own pace
Over 14 hours of educational content
Top-rated lectures with clear take-home messages covering the essential specialties
From Canada’s McMaster University
The home of evidence-based medicine (EBM) and one of the best medical schools in the world
Claim your CME credits by November 12, 2024 and receive the certificate of attendance
Redeem your credits at your convenience—24 hours a day, 7 days a week
31 world-renowned experts offering a broad perspective
Faculty from top-ranked medical universities and research centers sharing their insight and experience
Extra sessions: Medical Education Forum
Lectures and Q&As exploring the latest trends in medical education
Fascinating case reports from around the globe
20 presentations with surprising findings and clinical gems (part of the Best Case Report Contest)
Over 80 abstracts and digital posters
Submissions from 19 countries highlighting global medical trends and challenges (part of the Best Case Report Contest)
Comprehensive course materials
A convenient PDF course pack with presentations and takeaway messages
Free access to the McMaster Textbook of Internal Medicine
Overview of essential topics in internal medicine with over 800 chapters updated on the go
We have selected 3 excellent lectures as a sample of what you can expect:
- Prof. Dan Perri, McMaster University, Canada: Artificial intelligence (AI) in medicine: Where we are now and what future may bring
- Prof. Paul O’Byrne, McMaster University, Canada: Asthma exacerbations management
- Prof. Vijay Kunadian, Newcastle University, UK: Acute coronary syndromes management: 2024 update
These are open-access lectures (no login required). Click the button to play the selected video.
What’s included
- 31 lectures spanning 8 sessions covering the essential topics and updates in internal medicine
- Unrestricted 12-month on-demand access to all video recordings from the course
- Up to 22 CME credits (available through November 11, 2024)
- Certificate of attendance
- Extra session: Medical Education Forum (lectures and Q&As)
- Extra session: Young Talents in Internal Medicine. Best Case Report Contest 2024 (video presentations, abstracts, posters)
- Course materials in PDF
- 12-month access to the McMaster Textbook of Internal Medicine, including the website and mobile app
Total price: €200
How to join
- Go to www.mircim.eu/register
- Create a user account to register for MIRCIM 2024
- Buy access by selecting “MIRCIM 2024 virtual bundle” – standard or student fee
- Fill in your personal information and proceed to review your virtual cart
- Confirm your order and proceed to payment
- Log in to the virtual platform and enjoy your MIRCIM virtual experience.
- You can get your CME credits through November 11, 2024.
Great speakers, engaging, relevant topics.
It helps me to provide new methods of diagnosis and new recommendations for treatment of my patients.
The best part of this event was the fact that I can be part of this incredible experience where knowledge is shared by the most elite professors around the world and get the updates concerning the internal medicine guidelines as well as the latest research.
The possibility to discover new developments in internal medicine and to discuss it with world-class experts, clear and valuable presentations that provide data important in practice, explain recent meta-analysis.
After this event I’ve realized that as a medical doctor, we should be able to think outside of the box to give our patient the best treatment plan.
Agenda
All the presentations listed below are part of the online access bundle. You will also receive a link to downloadable content.
All lectures are in English.
Opening sessions
Day 1
Artificial intelligence in medicine: Where we are now and what future may bring
Prof. Dan Perri (McMaster University, Canada)
Day 2
Medical cannabis 2024 update: Benefits and dangers
Prof. Kevin Hill (Harvard Medical School, USA)
Session I: Current management of arterial hypertension
Session under the auspices of the European Society of Hypertension (ESH)
Chair: Prof. Andrzej Januszewicz (Vice President of ESH, Poland)
Thresholds for initiation of antihypertensive treatment and targets for the treatment
Prof. Giuseppe Mancia (University of Milano-Bicocca, Italy)
General recommendations for drug treatment in hypertension
Prof. Reinhold Kreutz (Charité – Medical University Berlin, Germany)
Perioperative management of hypertension and hypertensive emergencies
Prof. Maria Lorenza Muiesan (University of Brescia, Italy)
Management of hypertension in patients with cardiac diseases
Prof. Konstantinos Tsioufis (National and Kapodistrian University of Athens, Greece)
Questions & Answers
All speakers
Session II: Cardiology and Hematology
Acute coronary syndromes management: 2024 update
Prof. Vijay Kunadian (Newcastle University, UK)
Antithrombotic treatment: 2024 update
Prof. James Douketis (McMaster University, Canada)
Hypereosinophilia: A practical approach for internists
Prof. Florence Roufosse (Université Libre de Bruxelles, Belgium)
Questions & Answers
All speakers
Session III: Rheumatology and Nephrology
Session under the auspices of the International Society of Internal Medicine (ISIM)
Chair: Prof. Virginia Hood (President Elect of ISIM, USA)
Sharpening rheumatological diagnoses with point-of-care rheumatology ultrasonography (POCRUS)
Prof. Bhaskar Dasgupta (Southend University Hospital, UK)
Treating osteoarthritis: What works and what doesn’t work
Prof. Sharon L. Kolasinski (University of Pennsylvania – Perelman School of Medicine, USA)
Inflammatory rheumatic disease: When to search for malignancy
Prof. Kim Legault (McMaster University, Canada)
Nephrology update 2024
Prof. Jürgen Floege (RWTH Aachen University, Germany)
Questions & Answers
All speakers
Session IV: The Multimorbid Patient
Session under the auspices of the European Federation of Internal Medicine (EFIM)
Chair: Prof. Máximo Bernabeu-Wittel (Chair of the EFIM Multimorbidity Working Group, Spain)
Prescription appropriateness: A case-based practical tool
Prof. Jan Václavík (University Hospital Ostrava, Czech Republic)
Frequent clinical scenarios for deprescribing in elderly patients with multimorbidity
Dr. Annette Kurrle (Hochtaunus Kliniken Homburg, Germany)
Falls in elderly: What evaluation is needed
Prof. Jyotirmoy Pal (R.G. Kar Medical College, India)
Managing osteoporosis in patients with comorbidities
Prof. Alexandra Papaioannou (McMaster University, Canada)
Questions & Answers
All speakers
Session V: Pulmonology and Intensive Care
Chair: Prof. Roman Jaeschke (McMaster University, Canada)
Acute dyspnea: Emergency management
Prof. Simon Oczkowski (McMaster University, Canada)
Asthma exacerbations management
Prof. Paul O’Byrne (McMaster University, Canada)
Anaphylaxis and other life-threatening allergic emergencies: Current management
Prof. Derek Chu (McMaster University, Canada)
Questions & Answers
All speakers
Session VI: Diabetology and Endocrinology
Chair: Dr. Adri Kok (Past President of ISIM, South Africa)
Young-onset type 2 diabetes in adults: How to diagnose and treat
Prof. Leszek Czupryniak (Medical University of Warsaw, Poland)
Assessment and treatment of diabetic emergencies
Prof. René Rodríguez-Gutiérrez (Autonomous University of New Leon, Mexico)
Hyponatremia: An approach to diagnosis and management
Prof. Ally Prebtani (McMaster University, Canada)
Questions & Answers
All speakers
Session VII: Gastroenterology
Chair: Prof. Akbar Panju (McMaster University, Canada)
Managing gastroesophageal reflux disease: The state of the art
Prof. Paul Moayyedi (McMaster University, Canada)
Functional abdominal pain: How to diagnose and treat
Prof. Jan Tack (University of Leuven, Belgium)
Prevention and management of bleeding and thrombosis in patients with liver disease
Prof. Virginia Hernández-Gea (University of Barcelona, Spain)
Current management of chronic pancreatitis
Prof. Marianna Arvanitakis (Université Libre de Bruxelles, Belgium)
Session VIII: Infectious Diseases
Chair: Prof. Nishma Singhal (McMaster University, Canada)
Endocarditis: Current management according to the latest practice guidelines
Prof. Margarita Brida (University Hospital Centre Zagreb, Croatia)
Sepsis management: Practical tips for nonintensivists
Prof. Bram Rochwerg (McMaster University, Canada)
Current challenges in infectious diseases: What a non-specialist should know
Prof. Zain Chagla (McMaster University, Canada)
Unravelling travel vaccination
Prof. Somia Iqtadar (King Edward Medical University, Pakistan)
Questions & Answers
All speakers
Medical Education Forum: Teaching medicine at the bedside
Session under the auspices of the Society of Bedside Medicine
Chair: Prof. Ryszard Gellert (Director of the Centre of Postgraduate Medical Education, Poland)
Challenges and opportunities in giving feedback at the bedside
Prof. Maja Artandi (Co-President of the Society of Bedside Medicine, Stanford University, USA)
The 10-Minute Moment: A tool to assess physical examination skills at the bedside
Prof. Stephen Russell (Co-President of the Society of Bedside Medicine, University of Alabama at Birmingham, USA)
Challenges and opportunities in teaching and assessing physical examination skills in undergraduate medical education
Prof. Janet Record (Johns Hopkins University School of Medicine, USA)
POCUS: When does it perform better than the physical exam?
Prof. Ian Buchanan (McMaster University, Canada)
Questions and Answers
All speakers
Medical Education Forum: The evolution of competency-based medical education (CBME) from theory to practice and lessons learned
Chair: Prof. Reinold Gans (President of the European Board of Internal Medicine, the Netherlands)
CBME: The theory and rationale
Prof. Azim Gangji (McMaster University, Canada)
Implementation of CBME in the European context
Prof. Reinold Gans (President of the European Board of Internal Medicine, University Medical Center Groningen, the Netherlands)
Practicalities and challenges in implementing a CBME program: The Canadian context
Prof. Leslie Martin (McMaster University, Canada)
Panel discussion: Incorporating CBME - lessons learned
Prof. Azim Gangji, Prof. Leslie Martin, Prof. Reinold Gans
Closing remarks
Organizing Committee
Clinical Cases in Internal Medicine: Learning Through Practice
During this session 20 selected case reports submitted to the Best Case Report Contest are be presented by the authors and discussed by world-renowned experts. You can access all 80+ poster presentations online.
Chylothorax induced by dasatinib in a patient with chronic myeloid leukemia
Sergio Bueno (Argentina)
My worst nightmare: A case of granulomatous encephalitis
Stephanie Wang (Canada)
Mycoplasma-induced rash and mucositis (MIRM): A rare case in a Colombian patient
Maria José Orrego (Colombia)
Adrenocortical carcinoma with mineralocorticoid hypertension histologically mimicking pheochromocytoma
Anna Ouřadová (Czech Republic)
Can zucchini kill you?
Babeta Čápková (Czech Republic)
A case report of a rare cause of acute pancreatitis and hepatitis syndrome
Livia Lontai (Hungary)
An unusual case of hypovolemic shock: Strongyloides hyperinfection syndrome
Vaibhav Agarwal (India)
Acquired Gerbode defect following a high-velocity motor vehicle accident
John McCormick (Ireland)
Recurrent haemoptysis and lung ground-glass opacity in a 36-year-old female
Sile Toland (Ireland)
Looks, sounds, smells like lymphoproliferative disease and potentially as lethal in the elderly
Rozan Yahya (Israel)
Mixed connective tissue disease coexistence with refractory TTP: Rare coexistence, diagnostic dilemma, and therapeutic delay lead to worse prognosis in resource-limited health-care areas
Romail Shahid (Pakistan)
Coexistence of central diabetes insipidus and cerebral salt wasting syndrome
Joanna Rymuza (Poland)
Adrenal gland tumors—so common yet still surprising: A rare case of alveolar echinococcosis of the adrenal gland
Michał Olejarz (Poland)
A mixed heart: A dual type of cardiac amyloidosis
Ines Miranda (Portugal)
Down the rabbit hole: A rare case of PUO
Nisha George (Scotland)
Plasmapheresis as a bridge to thyroidectomy in a patient with severe type II amiodarone-induced thyrotoxicosis, concurrent ischemic cardiomyopathy, and refractory ventricular tachycardia
Tariq Ramtoola (Scotland)
Myopericarditis in an ultra-endurance runner: A case of late-onset systemic lupus erythematosus
Peter Kromka (Slovakia)
Takayasu arteritis: A clot or not? A case report
Anri Gerber (South Africa)
Candida pericarditis with tamponade: A case report of a complicated malignant oesophago-pericardial fistula
Nicola Wills (South Africa)
A case report of atypically presented Lyme disease
Ugur Arzu Kulu (Turkey)
The McMaster Textbook is the first Canadian textbook of internal medicine from McMaster University. Designed for for clinicians, including internists, family physicians, front-line acute health-care workers, medical students and residents, and other medical professionals.
1. Signs and Symptoms
1.1. Ascites
1.2. Ataxia
1.3. Consciousness Disturbances
1.3.1. Impaired Consciousness: General Considerations
1.3.2. Loss of Consciousness
1.3.2.1. Coma
1.3.2.2. Syncope and Other Causes of Transient Loss of Consciousness
1.4. Constipation
1.5. Cough
1.6. Cyanosis
1.7. Diarrhea
1.8. Dyspepsia
1.9. Dysphagia
1.9.1. Dysphagia: General Considerations
1.9.2. Management of Dysphagia: A Speech-Language Pathologist Perspective
1.10. Dyspnea: General Considerations
1.11. Edema
1.12. Fever of Unknown Origin (FUO)
1.13. Fingers, Deformed
1.13.1. Clubbing
1.13.2. Fingers in Rheumatic Diseases
1.14. Gynecomastia
1.15. Heart Auscultation
1.15.1. Heart Murmurs
1.15.1.1. Continuous (Machinery) Murmurs
1.15.1.2. Diastolic Murmurs
1.15.1.3. Systolic Murmurs
1.15.2. Heart Sounds
1.15.3. Pericardial Friction Rub
1.16. Hematuria
1.17. Hemoptysis
1.18. Hepatomegaly
1.19. Hiccups (Singultus)
1.20. Hirsutism
1.21. Hoarseness (Dysphonia)
1.22. Jaundice
1.23. Jugular Venous Distention
1.24. Lymphadenopathy
1.25. Meningeal Irritation Signs
1.26. Micturition (Voiding) Abnormalities
1.27. Muscular Weakness (Paresis and Paralysis)
1.28. Nausea and Vomiting
1.29. Pain
1.29.1. Abdominal Pain: General Considerations
1.29.2. Chest Pain
1.29.3. Headache
1.29.4. Otalgia
1.29.5. Pain Management: Basic Principles
1.30. Palpitations
1.31. Pruritus
1.32. Pulse, Abnormal
1.33. Respirations
1.34. Respiratory Sounds
1.35. Sensory Disturbances
1.36. Splenomegaly
1.37. Subcutaneous Emphysema
1.38. Thirst
1.39. Vertigo
2. Allergy and Immunology
2.1. Allergic Rhinitis
2.2. Anaphylaxis and Anaphylactic Shock
2.3. Angioedema
2.4. Food Hypersensitivity
2.5. Immunodeficiency Disorders
2.6. Serum Sickness
2.7. Urticaria
3. Cardiovascular Diseases
3.1. Anticoagulant Treatment
3.1.1. Anticoagulant Agents
3.1.1.1. Direct Thrombin Inhibitors
3.1.1.2. Factor Xa Inhibitors
3.1.1.3. Heparins
3.1.1.4. Vitamin K Antagonists (VKAs)
3.1.2. Anticoagulant Treatment and Regional Anesthesia
3.1.3. Perioperative Direct Oral Anticoagulant (DOAC) Management
3.2. Automaticity and Conduction Disorders
3.2.1. Atrioventricular Blocks
3.2.2. Intraventricular Blocks
3.2.3. Sinus Node Dysfunction
3.3. Cardiac Arrest
3.4. Cardiac Arrhythmias
3.4.1. Sudden Cardiac Death
3.4.2. Supraventricular Arrhythmias
3.4.2.1. Supraventricular Premature Beats
3.4.2.2. Supraventricular Tachycardias
3.4.2.2.1. Atrial Fibrillation (AF)
3.4.2.2.2. Atrial Flutter (AFL)
3.4.2.2.3. Atrial Tachycardia (AT)
3.4.2.2.4. Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
3.4.2.2.5. Manifest and Concealed Accessory Pathways
3.4.2.2.6. Sinus Tachyarrhythmias
3.4.3. Ventricular Arrhythmias
3.4.3.1. Brugada Syndrome
3.4.3.2. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
3.4.3.3. Congenital Long-QT Syndrome (LQTS)
3.4.3.4. Idiopathic Ventricular Fibrillation (IVF)
3.4.3.5. Idiopathic Ventricular Tachycardia
3.4.3.6. Ventricular Arrhythmia Following Myocardial Infarction
3.4.3.7. Ventricular Tachycardia in Patients With Nonischemic Cardiomyopathy
3.5. Cardiac Tamponade
3.6. Cardiomyopathies
3.6.1. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
3.6.2. Dilated Cardiomyopathy (DCM)
3.6.3. Hypertrophic Cardiomyopathy (HCM)
3.6.4. Restrictive Cardiomyopathy (RCM)
3.6.5. Unclassified Cardiomyopathies
3.7. Congenital Heart Disease in Adults
3.7.1. Atrial Septal Defect (ASD)
3.7.2. Coarctation of the Aorta
3.7.3. Ebstein Anomaly
3.7.4. Eisenmenger Syndrome
3.7.5. Patent Ductus Arteriosus (PDA)
3.7.6. Patent Foramen Ovale (PFO)
3.7.7. Tetralogy of Fallot
3.7.8. Transposition of Great Arteries (TGA)
3.7.9. Ventricular Outflow Tract Obstruction
3.7.9.1. Left Ventricular Outflow Tract Obstruction
3.7.9.2. Right Ventricular Outflow Tract Obstruction
3.7.10. Ventricular Septal Defect (VSD)
3.8. Heart Failure (HF)
3.8.1. Acute Heart Failure (AHF)
3.8.2. Chronic Heart Failure
3.9. Hypertension
3.9.1. Essential Hypertension
3.9.2. Renal Parenchymal Hypertension
3.9.3. Renovascular Hypertension
3.10. Infective Endocarditis (IE)
3.11. Ischemic Heart Disease (IHD)
3.11.1. Acute Coronary Syndrome (ACS)
3.11.1.1. Non–ST-Segment Elevation Myocardial Infarction (NSTEMI) and Unstable Angina (UA)
3.11.1.2. ST-Segment Elevation Myocardial Infarction (STEMI)
3.11.2. Stable Coronary Artery Disease (Chronic Coronary Syndromes)
3.11.2.1. Microvascular Angina
3.11.2.2. Stable Angina Pectoris
3.11.2.3. Vasospastic Angina (Prinzmetal Variant Angina)
3.12. Lipid Disorders
3.12.1. Atherogenic Dyslipidemia
3.12.2. Hypercholesterolemia
3.12.3. Severe Hypertriglyceridemia
3.13. Lymphatic Vessel Diseases
3.13.1. Lymphangitis
3.13.2. Lymphedema
3.14. Myocarditis
3.15. Pericarditis
3.16. Prevention of Cardiovascular Diseases
3.17. Shock
3.17.1. Cardiogenic Shock
3.17.2. Hypovolemic Shock
3.17.2.1. Hemorrhagic Shock
3.17.3. Obstructive Shock
3.18. Valvular Heart Disease
3.18.1. Aortic Valve Disease
3.18.1.1. Aortic Regurgitation
3.18.1.2. Aortic Stenosis
3.18.1.3. Mixed Aortic Stenosis and Regurgitation
3.18.2. Mitral Valve Disease
3.18.2.1. Mitral Regurgitation
3.18.2.2. Mitral Stenosis
3.18.2.3. Mitral Valve Prolapse
3.18.2.4. Mixed Mitral Valve Disease
3.18.3. Multivalvular Disease
3.18.4. Tricuspid Valve Disease
3.18.4.1. Tricuspid Regurgitation
3.18.4.2. Tricuspid Stenosis
3.19. Vascular Diseases, Peripheral
3.19.1. Aortic Diseases
3.19.1.1. Aortic Aneurysms
3.19.1.1.1. Aortic Pseudoaneurysm
3.19.1.1.2. Contained Rupture of Aortic Aneurysm
3.19.1.2. Acute Aortic Syndrome
3.19.1.2.1. Aortic Dissection
3.19.1.2.2. Intramural Hematoma
3.19.1.2.3. Penetrating Aortic Ulcer
3.19.2. Carotid and Vertebral Artery Stenosis
3.19.3. Lower Limb Ischemia
3.19.3.1. Acute Lower Limb Ischemia
3.19.3.2. Lower Extremity Peripheral Artery Disease (PAD)
3.19.4. Microcirculation Disorders
3.19.4.1. Erythromelalgia
3.19.4.2. Livedo Reticularis
3.19.4.3. Raynaud Phenomenon
3.19.5. Thromboangiitis Obliterans
3.19.6. Venous Diseases
3.19.6.1. Chronic Venous Insufficiency
3.19.6.2. Superficial Thrombophlebitis
3.19.6.3. Superior Vena Cava Syndrome
3.20. Venous Thromboembolism (VTE)
3.20.1. Deep Vein Thrombosis (DVT)
3.20.2. Pulmonary Embolism (PE)
3.20.3. Venous Thromboembolism: Primary Prevention
4. Dermatology
4.1. Bullous Pemphigoid
4.2. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
4.3. Fixed Drug Eruption
4.4. Pemphigus Vulgaris
4.5. Psoriasis
4.6. Pyoderma Gangrenosum
4.7. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
5. Electrolyte, Fluid, and Acid-Base Balance Disorders
5.1. Acid-Base Disorders
5.1.1. Metabolic Acidosis
5.1.2. Metabolic Alkalosis
5.1.3. Respiratory Acidosis
5.1.4. Respiratory Alkalosis
5.2. Electrolyte Disturbances
5.2.1. Calcium Disturbances
5.2.1.1. Hypercalcemia
5.2.1.2. Hypocalcemia
5.2.2. Magnesium Disturbances
5.2.2.1. Hypermagnesemia
5.2.2.2. Hypomagnesemia
5.2.3. Phosphate Disturbances
5.2.3.1. Hyperphosphatemia
5.2.3.2. Hypophosphatemia
5.2.4. Potassium Disturbances
5.2.4.1. Hyperkalemia
5.2.4.2. Hypokalemia
5.2.5. Sodium Disturbances
5.2.5.1. Hypernatremia
5.2.5.2. Hyponatremia
5.3. Fluid Disturbances
5.3.1. Dehydration
5.3.1.1. Isotonic Dehydration
5.3.1.2. Hypertonic Dehydration
5.3.1.3. Hypotonic Dehydration
5.3.2. Water Overload
5.3.2.1. Hypertonic Water Overload
5.3.2.2. Hypotonic Water Overload (Water Intoxication)
5.3.2.3. Isotonic Water Overload
6. Endocrinology
6.1. Adrenal Gland Diseases
6.1.1. Adrenal Cancer
6.1.2. Adrenal Incidentalomas
6.1.3. Adrenal Insufficiency
6.1.3.1. Acute Adrenal Insufficiency (Adrenal Crisis)
6.1.3.2. Central Adrenal Insufficiency
6.1.3.3. Primary Adrenal Insufficiency (Addison Disease)
6.1.4. Cushing Syndrome
6.1.5. Hypoaldosteronism
6.1.6. Pheochromocytoma and Paraganglioma
6.1.7. Primary Aldosteronism
6.2. Glucose Metabolism Disorders
6.2.1. Diabetes Mellitus (DM)
6.2.2. Complications of Diabetes Mellitus, Acute
6.2.2.1. Diabetic Ketoacidosis (DKA)
6.2.2.2. Drug-Induced Hypoglycemia
6.2.2.3. Hyperglycemic Hyperosmolar State (HHS)
6.2.2.4. Lactic Acidosis
6.2.3. Complications of Diabetes Mellitus, Chronic
6.2.3.1. Diabetic Foot Syndrome
6.2.3.2. Diabetic Kidney Disease
6.2.3.3. Diabetic Neuropathy
6.2.3.4. Diabetic Retinopathy
6.2.4. Diabetes Mellitus in Pregnant Patients
6.2.4.1. Diabetes Mellitus in Pregnancy
6.2.4.2. Gestational Diabetes Mellitus (GDM)
6.2.5. Nondiabetic Hypoglycemia
6.3. Hypothalamus and Pituitary Diseases
6.3.1. Acromegaly
6.3.2. Cushing Disease
6.3.3. Diabetes Insipidus (DI)
6.3.4. Hyperprolactinemia
6.3.5. Hypopituitarism
6.3.6. Pituitary Incidentalomas
6.3.7. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
6.4. Metabolic Syndrome
6.5. Obesity
6.5.1. Obesity: General Considerations
6.5.2. Obesity: Lifestyle and Medical Treatment
6.5.3. Obesity: Surgical and Nonsurgical Weight Loss Procedures
6.5.3.1. Obesity: Postsurgical Complications
6.6. Parathyroid Gland Diseases
6.6.1. Hyperparathyroidism
6.6.1.1. Primary Hyperparathyroidism
6.6.1.2. Secondary Hyperparathyroidism
6.6.1.3. Tertiary Hyperparathyroidism
6.6.2. Hypoparathyroidism
6.7. Thyroid Gland Diseases
6.7.1. Hypothyroidism
6.7.2. Goiter, Nontoxic Multinodular
6.7.3. Thyroid Cancer
6.7.4. Thyroiditis
6.7.4.1. Acute Thyroiditis
6.7.4.2. Chronic Autoimmune Thyroiditis (Hashimoto Thyroiditis)
6.7.4.3. Chronic Thyroiditis, Other Types
6.7.4.4. Subacute Painful Thyroiditis (de Quervain Thyroiditis)
6.7.5. Thyrotoxicosis and Hyperthyroidism
6.7.5.1. Graves Disease
6.7.5.2. Toxic Multinodular Goiter (TMG)
6.7.5.3. Toxic Thyroid Nodule
7. Gastroenterology
7.1. Bile Duct and Gallbladder Diseases
7.1.1. Acute Cholangitis
7.1.2. Acute Cholecystitis
7.1.3. Ampullary Carcinoma
7.1.4. Cholangiocarcinoma
7.1.5. Gallbladder Cancer
7.1.6. Gallstones
7.1.6.1. Choledocholithiasis
7.1.6.2. Cholelithiasis
7.1.7. Primary Sclerosing Cholangitis
7.1.8. Sphincter of Oddi Dysfunction
7.2. Gastrointestinal Diseases
7.2.1. Esophageal Diseases
7.2.1.1. Eosinophilic Esophagitis (EoE)
7.2.1.2. Esophageal Cancer
7.2.1.3. Esophageal Diverticula
7.2.1.4. Esophageal Motility Disorders
7.2.1.4.1. Achalasia
7.2.1.4.2. Esophageal Peristalsis Major Disorders: Distal Esophageal Spasm, Hypercontractile (Jackhammer) Esophagus
7.2.1.5. Gastroesophageal Reflux Disease (GERD)
7.2.2. Gastric Diseases
7.2.2.1. Gastric Cancer
7.2.2.2. Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
7.2.2.3. Gastritis and Gastropathy
7.2.2.3.1. Acute Hemorrhagic/Erosive and Stress-Related Gastropathy
7.2.2.3.2. Autoimmune Gastritis
7.2.2.3.3. Bile Reflux Gastropathy
7.2.2.3.4. Gastritis Due to Helicobacter pylori Infection
7.2.2.4. Gastroparesis
7.2.2.5. Peptic Ulcer Disease (PUD)
7.2.2.6. Zollinger-Ellison Syndrome (ZES)
7.2.3. Intestinal Diseases
7.2.3.1. Anorectal Diseases
7.2.3.1.1. Anal Cancer
7.2.3.1.2. Anal Fissures
7.2.3.1.3. Anorectal Abscess and Fistula in Ano
7.2.3.1.4. Hemorrhoids
7.2.3.2. Celiac Disease
7.2.3.3. Colonic Diverticula
7.2.3.4. Colorectal Cancer
7.2.3.5. Colorectal Cancer Screening
7.2.3.6. Gastrointestinal Bleeding
7.2.3.7. Gastrointestinal Foreign Bodies
7.2.3.8. Gastrointestinal Infections
7.2.3.8.1. Acute Appendicitis
7.2.3.8.2. Acute Infectious Diarrhea: General Considerations
7.2.3.8.3. Antibiotic-Associated Diarrhea
7.2.3.8.4. Bacterial Food Poisoning
7.2.3.8.5. Clostridioides difficile Infection (CDI)
7.2.3.8.6. Gastrointestinal Infections in Immunocompromised Patients
7.2.3.8.7. Nosocomial Diarrhea
7.2.3.8.8. Traveler’s Diarrhea
7.2.3.9. Gastrointestinal Obstruction
7.2.3.9.1. Adynamic Ileus
7.2.3.9.2. Mechanical Intestinal Obstruction
7.2.3.10. Inflammatory Bowel Disease (IBD)
7.2.3.10.1. Crohn Disease
7.2.3.10.2. Ulcerative Colitis (UC)
7.2.3.11. Intestinal Ischemia
7.2.3.11.1. Acute Mesenteric (Small Bowel) Ischemia
7.2.3.11.2. Chronic Mesenteric (Small Bowel) Ischemia
7.2.3.11.3. Colonic Ischemia
7.2.3.12. Irritable Bowel Syndrome (IBS)
7.2.3.13. Microscopic Colitis
7.2.3.14. Protein-Losing Enteropathy
7.2.3.15. Short Bowel Syndrome
7.2.3.16. Small Intestinal Bacterial Overgrowth (SIBO)
7.3. Liver Diseases
7.3.1. Acute Liver Failure (ALF)
7.3.2. Alcoholic Liver Disease
7.3.3. Autoimmune Hepatitis (AIH)
7.3.4. Cirrhosis
7.3.5. Drug-Induced Liver Injury (DILI)
7.3.6. Hepatic Cysts
7.3.6.1. Hepatic Cysts: General Considerations
7.3.6.2. Intrahepatic Biliary Cysts
7.3.6.3. Parasitic Hepatic Cysts
7.3.6.4. Polycystic Liver Disease
7.3.6.5. Posttraumatic Hepatic Cysts
7.3.6.6. Simple Hepatic Cysts
7.3.7. Hepatic Tumors
7.3.7.1. Focal Nodular Hyperplasia
7.3.7.2. Hemangioma
7.3.7.3. Hepatocellular Adenoma
7.3.7.4. Hepatocellular Carcinoma
7.3.7.5. Metastatic Cancers
7.3.8. Hepatic Vascular Diseases
7.3.8.1. Budd-Chiari Syndrome (Including Hepatic Vein Thrombosis)
7.3.8.2. Idiopathic Noncirrhotic Portal Hypertension
7.3.8.3. Portal Vein Thrombosis (PVT)
7.3.9. Iron Overload
7.3.9.1. Hereditary Hemochromatosis
7.3.9.2. Secondary Iron Overload
7.3.10. Nonalcoholic Fatty Liver Disease (NAFLD)
7.3.11. Primary Biliary Cholangitis (PBC)
7.3.12. Viral Hepatitis
7.3.12.1. Acute Hepatitis A
7.3.12.2. Acute Hepatitis B
7.3.12.3. Acute Hepatitis C
7.3.12.4. Acute Hepatitis D
7.3.12.5. Acute Hepatitis E
7.3.12.6. Chronic Hepatitis B
7.3.12.7. Chronic Hepatitis C
7.3.13. Wilson Disease
7.4. Pancreatic Diseases
7.4.1. Acute Pancreatitis
7.4.2. Autoimmune Pancreatitis
7.4.3. Chronic Pancreatitis
7.4.3.1. Pancreatic Cancer
7.4.3.2. Pancreatic Adenocarcinoma
7.4.4. Pancreatic Cysts and Pseudocysts
8. Geriatrics
8.1. Frailty
8.2. Polypharmacy and Deprescribing
9. Hematology
9.1. Anemia and Other Nonmalignant Blood Disorders
9.1.1. Anemia: General Considerations
9.1.2. Anemia of Chronic Disease
9.1.3. Aplastic Anemias
9.1.3.1. Aplastic Anemia
9.1.3.2. Pure Red Cell Aplasia
9.1.4. Hemolytic Anemias
9.1.4.1. Hemolytic Anemia: General Considerations
9.1.4.2. Sickle Cell Disease (SCD)
9.1.4.3. Thalassemia
9.1.5. Iron Deficiency Anemia
9.1.6. Megaloblastic Anemias
9.1.6.1. Cobalamin Deficiency
9.1.6.2. Folate Deficiency
9.1.7. Sideroblastic Anemia
9.2. Bleeding Disorders
9.2.1. Acquired Coagulation Disorders
9.2.1.1. Acquired Hemophilia A
9.2.1.2. Disseminated Intravascular Coagulation (DIC)
9.2.2. Acquired Thrombocytopenic Bleeding Disorders
9.2.2.1. Platelet Disorders: General Considerations
9.2.2.2. Immune Thrombocytopenia (ITP)
9.2.2.3. Thrombocytopenia Caused by Decreased Platelet Production
9.2.3. Inherited Coagulation Disorders Associated with Bleeding
9.2.3.1. Hemophilia A and Hemophilia B
9.2.3.2. Von Willebrand Disease (vWD)
9.2.4. Thrombophilia (Hypercoagulable States)
9.2.5. Vascular Purpuras
9.3. Lymphoid Neoplasms
9.3.1. Acute Lymphoblastic Leukemia (ALL)
9.3.2. Chronic Lymphocytic Leukemia (CLL)
9.3.3. Hemophagocytic Lymphohistiocytosis (HLH)
9.3.4. Hodgkin Lymphoma (HL)
9.3.5. Monoclonal Immunoglobulin Deposition Disease
9.3.6. Non-Hodgkin Lymphoma (NHL)
9.3.7. Plasma Cell Myeloma (PCM)
9.4. Myeloid Neoplasms
9.4.1. Acute Myeloid Leukemia (AML)
9.4.2. Chronic Eosinophilic Leukemia (CEL) (and Other Causes of Hypereosinophilia)
9.4.3. Chronic Myeloid Leukemia (CML)
9.4.4. Chronic Myelomonocytic Leukemia (CMML)
9.4.5. Essential Thrombocythemia (ET)
9.4.6. Mastocytosis
9.4.7. Myelodysplastic Syndromes (MDSs)
9.4.8. Polycythemia Vera (PV)
9.4.9. Primary Myelofibrosis (PMF)
9.5. Porphyria, Acute Intermittent
9.6. Thrombotic Microangiopathies
9.6.1. Hemolytic-Uremic Syndrome (HUS)
9.6.2. Thrombotic Thrombocytopenic Purpura (TTP)
9.7. Transfusion of Blood and Blood Products
9.7.1. Granulocyte Concentrate
9.7.2. Irradiation of Blood Products
9.7.3. Packed Red Blood Cell (PRBC) Products
9.7.3.1. Leukocyte-Reduced Packed Red Blood Cell (PRBC) Products
9.7.3.2. Packed Red Blood Cell (PRBC) Products
9.7.3.3. Washed Packed Red Blood Cells (PRBC)
9.7.4. Plasma and Its Derivatives
9.7.4.1. Cryoprecipitate
9.7.4.2. Frozen Plasma (FP) and Solvent/Detergent (S/D) Plasma
9.7.4.3. Human Albumin
9.7.4.4. Nonspecific Immunoglobulins
9.7.4.5. Prothrombin Complex Concentrates (PCCs)
9.7.4.5.1. Activated Prothrombin Complex Concentrates (aPCCs)
9.7.4.6. Rh0(D) Immunoglobulin (RhIG)
9.7.5. Platelet Concentrates
9.7.5.1. Leukocyte-Reduced Platelet Concentrate
9.7.5.2. Reconstituted Platelet Concentrate
9.7.5.3. Refractoriness to Platelet Transfusions
9.7.5.4. Washed Platelet Concentrate
9.7.6. Transfusion Reactions and Procedure
9.7.7. Whole Blood
10. Infectious Diseases
10.1. Acquired Immunodeficiency Syndrome (AIDS)
10.2. Antimicrobial Agents
10.2.1. Antibacterial Agents
10.2.2. Antifungal Agents
10.2.3. Antiparasitic Agents
10.2.3.1. Agents with Activity Against Ectoparasites
10.2.3.2. Anthelmintic Agents
10.2.3.3. Antiprotozoal Agents
10.2.4. Antiviral Agents
10.3. Bacterial Diseases
10.3.1. Brucellosis
10.3.2. Cholera
10.3.3. Clostridium spp Infections
10.3.3.1. Botulism
10.3.3.2. Clostridial Myonecrosis (Gas Gangrene)
10.3.3.3. Tetanus
10.3.4. Enteric (Typhoid) Fever
10.3.5. Leprosy
10.3.6. Melioidosis
10.3.7. Nocardiosis
10.3.8. Scrub Typhus
10.3.9. Sexually Transmitted Bacterial Diseases
10.3.9.1. Gonorrhea
10.3.9.2. Lymphogranuloma Venereum (LGV)
10.3.9.3. Sexually Transmitted Chlamydial Infections Other Than Lymphogranuloma Venereum (LGV)
10.3.9.4. Syphilis
10.3.10. Skin and Soft Tissue Infections
10.3.10.1. Nonpurulent Skin and Soft Tissue Infections: Erysipelas and Cellulitis
10.3.10.2. Purulent Skin and Soft Tissue Infections: Furuncles, Carbuncles, and Cutaneous Abscesses
10.3.11. Spirochetal Infections
10.3.11.1. Leptospirosis
10.3.11.2. Lyme Borreliosis
10.3.12. Streptococcal Infections
10.3.12.1. Rheumatic Fever
10.3.12.2. Scarlet Fever
10.4. Central Nervous System (CNS) Infections
10.4.1. Encephalitis
10.4.2. Focal Infections of the Central Nervous System
10.4.2.1. Brain Abscess
10.4.2.2. Neurocysticercosis
10.4.2.3. Subdural Empyema
10.4.3. Meningitis
10.4.4. Myelitis
10.5. Febrile Neutropenia
10.6. Immunization, Vaccination, and Infection Prevention
10.6.1. Immunization and Selected Vaccinations in Adults
10.6.1.1. Immunization Prior to Travel to Endemic Areas
10.6.1.2. Vaccines: Bacterial Diseases
10.6.1.2.1. Vaccines: Cholera
10.6.1.2.2. Vaccines: Diphtheria and Tetanus
10.6.1.2.3. Vaccines: Enteric (Typhoid) Fever
10.6.1.2.4. Vaccines: Neisseria meningitidis (Meningococcal) Infections
10.6.1.2.5. Vaccines: Pertussis
10.6.1.2.6. Vaccines: Pneumococcal Infections
10.6.1.3. Vaccines: Viral Diseases
10.6.1.3.1. Vaccines: COVID-19
10.6.1.3.2. Vaccines: Hepatitis A
10.6.1.3.3. Vaccines: Hepatitis B
10.6.1.3.4. Vaccines: Human Papillomavirus
10.6.1.3.5. Vaccines: Japanese Encephalitis
10.6.1.3.6. Vaccines: Measles, Mumps, and Rubella (MMR)
10.6.1.3.7. Vaccines: Poliomyelitis
10.6.1.3.8. Vaccines: Rabies
10.6.1.3.9. Vaccines: Seasonal Influenza
10.6.1.3.10. Vaccines: Tick-Borne Encephalitis
10.6.1.3.11. Vaccines: Varicella Zoster (Chickenpox and Shingles)
10.6.1.3.12. Vaccines: Yellow Fever
10.6.2. Infection Prevention Among Medical Staff
10.6.2.1. Nonspecific Methods of Infection Prevention Among Medical Staff
10.6.2.2. Occupational Exposures to Blood-Borne Viral Infections
10.6.3. Nonspecific Insect and Tick Bite Precautions
10.7. Intravascular Catheter–Related Infections
10.8. Mycoses
10.8.1. Superficial Mycoses
10.8.1.1. Dermatophytoses
10.8.1.2. Tinea Versicolor
10.8.1.3. Sporotrichosis
10.8.1.4. Superficial Candidiasis
10.8.2. Systemic Mycoses
10.8.2.1. Candidiasis
10.8.2.2. Cryptococcosis
10.8.2.3. Histoplasmosis
10.8.2.4. Mucormycosis
10.9. Parasitic Diseases
10.9.1. Ectoparasitic Infestations
10.9.1.1. Pediculosis
10.9.1.2. Scabies
10.9.2. Helminthiases
10.9.2.1. Alveolar Echinococcosis
10.9.2.2. Anisakiasis
10.9.2.3. Ascariasis
10.9.2.4. Cystic Echinococcosis
10.9.2.5. Cysticercosis
10.9.2.6. Enterobiasis
10.9.2.7. Filarial Infections
10.9.2.8. Hookworm Infections
10.9.2.9. Tapeworm Infections
10.9.2.10. Toxocariasis
10.9.2.11. Trichinellosis
10.9.2.12. Trichuriasis
10.9.3. Protozoal Diseases
10.9.3.1. Amoebiasis
10.9.3.2. Balantidiasis
10.9.3.3. Blastocystosis
10.9.3.4. Giardiasis
10.9.3.5. Leishmaniasis
10.9.3.6. Malaria
10.9.3.7. Toxoplasmosis
10.9.3.8. Trichomoniasis
10.10. Sepsis and Septic Shock
10.11. Viral Diseases
10.11.1. Chikungunya Fever
10.11.2. Common Cold (Nonspecific Infections of the Upper Respiratory Tract)
10.11.3. Coronavirus Infections
10.11.3.1. Coronavirus Disease 2019 (COVID-19)
10.11.3.2. Middle East Respiratory Syndrome (MERS)
10.11.4. Coxsackie Virus Infections
10.11.5. Herpes Virus Infections
10.11.5.1. Cytomegalovirus Infections
10.11.5.2. Herpes Simplex Virus (HSV) Infections
10.11.5.3. Herpes Zoster
10.11.5.4. Infectious Mononucleosis and Other Manifestations of Epstein-Barr Virus Infection
10.11.5.5. Varicella
10.11.6. Human Adenovirus Infections
10.11.7. Human Papillomavirus (HPV) Infection
10.11.8. Influenza
10.11.9. Japanese Encephalitis
10.11.10. Measles
10.11.11. Molluscum Contagiosum
10.11.12. Mumps
10.11.13. Parvovirus B19–Related Diseases
10.11.14. Rabies
10.11.15. Rubella
10.11.16. Tick-Borne Encephalitis (TBE)
10.11.17. Viral Hemorrhagic Fevers
10.11.17.1. Dengue
11. Nephrology
11.1. Acute Kidney Injury (AKI)
11.2. Chronic Kidney Disease (CKD)
11.3. Glomerular Diseases
11.3.1. Congenital Glomerulopathies
11.3.1.1. Alport Syndrome
11.3.1.2. Fabry Disease
11.3.1.3. Thin Basement Membrane Disease
11.3.2. Nephrotic Syndrome
11.3.3. Rapidly Progressive Glomerulonephritis (RPGN)
11.3.4. Specific Pathologies
11.3.4.1. Focal Segmental Glomerulosclerosis
11.3.4.2. IgA Nephropathy
11.3.4.3. Lupus Nephritis
11.3.4.4. Membranoproliferative Glomerulonephritis (MPGN)
11.3.4.5. Membranous Nephropathy
11.3.4.6. Minimal Change Disease (MCD)
11.3.4.7. Postinfectious Glomerulonephritis
11.3.4.8. Renal Amyloidosis
11.4. Kidney Transplant
11.5. Nephrolithiasis
11.6. Obstructive Nephropathy
11.7. Renal Cysts
11.7.1. Acquired Cystic Kidney Disease
11.7.2. Autosomal Dominant Polycystic Kidney Disease (ADPKD)
11.7.3. Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)
11.7.4. Medullary Sponge Kidney
11.7.5. Simple Renal Cyst
11.8. Tubulointerstitial Nephritis
11.8.1. Acute Interstitial Nephritis (AIN)
11.8.2. Chronic Interstitial Nephritis (CIN)
11.9. Tubulopathies
11.9.1. Bartter and Gitelman Syndromes
11.9.2. Cystinosis
11.9.3. Cystinuria
11.9.4. Familial Hypophosphatemic Rickets
11.9.5. Fanconi Syndrome
11.9.6. Nephrogenic Diabetes Insipidus (NDI)
11.9.7. Renal Glycosuria
11.9.8. Renal Tubular Acidosis
11.9.8.1. Distal (Type 1) Renal Tubular Acidosis (dRTA)
11.9.8.2. Hyperkalemic (Type 4) Renal Tubular Acidosis (RTA)
11.9.8.3. Proximal (Type 2) Renal Tubular Acidosis (pRTA)
11.10. Urinary Tract Infections (UTIs)
11.10.1. Asymptomatic Bacteriuria
11.10.2. Candiduria
11.10.3. Catheter-Associated Urinary Tract Infection
11.10.4. Complicated Urinary Tract Infection
11.10.5. Complications of Urinary Tract Infections
11.10.6. Cystitis
11.10.6.1. Nonbacterial Cystitis
11.10.6.2. Recurrent Cystitis in Women
11.10.6.3. Uncomplicated Cystitis
11.10.7. Genitourinary Tuberculosis
11.10.8. Uncomplicated Acute Pyelonephritis
11.10.9. Urethritis
11.10.10. Urinary Tract Infections in Patients with Spinal Cord Injury
11.10.11. Urinary Tract Infections in Pregnant Women
11.11. Urinary Tract Neoplasms
11.11.1. Cancer of the Renal Pelvis and Ureter
11.11.2. Renal Cell Carcinoma
11.11.3. Urethral Cancer
11.11.4. Urinary Bladder Cancer
12. Neurology
12.1. Idiopathic Intracranial Hypertension
12.2. Parkinson Disease
12.3. Seizures, Epilepsy, Status Epilepticus
12.3.1. Acute Seizures
12.3.2. Seizures and Epilepsy
12.3.3. Status Epilepticus
12.4. Stroke
13. Oncology: Medical Complications of Treatment
13.1. Cutaneous Eruptions Caused by Epidermal Growth Factor Receptor (EGFR) Inhibitors
13.2. Immune Checkpoint Inhibitors and Associated Immune-Related Adverse Events
13.3. Nausea and Vomiting in the Oncology Patient
13.4. Tumor Lysis Syndrome (TLS)
14. Palliative Care
14.1. Dyspnea in Palliative and End-of-Life Care
14.2. Last Days and Hours
14.2.1. Diagnosis of Death
14.3. Palliative Sedation: The Canadian Perspective
15. Pregnancy-Related Conditions
15.1. Amniotic Fluid Embolism (AFE)
15.2. Peripartum Cardiomyopathy (PPCM)
15.3. Pregnancy-Related Hypertension
15.3.1. Eclampsia
15.3.2. Preeclampsia
15.4. Pregnancy-Related Liver Disease
16. Psychiatry
16.1. Psychiatric Examination
16.2. Adverse Effects of Psychotropic Medications: Extrapyramidal Symptoms, Catatonia, Serotonin Syndrome, and Neuroleptic Malignant Syndrome
16.3. Anxiety and Related Disorders in Medical Settings
16.4. Approach to the Agitated Patient
16.5. Approach to the Difficult Patient
16.6. Bipolar Disorders
16.7. Cognitive Assessment in Medical Settings
16.8. Delirium
16.9. Dementia
16.9.1. Dementia: General Considerations
16.9.2. Dementia: Neuropsychiatric Symptoms
16.10. Depressive Disorders
16.11. Eating Disorders
16.12. Insomnia
16.13. Medical Care of the Seriously Mentally Ill
16.14. Medical Practice and the Law
16.15. Perinatal Depressive and Anxiety Disorders
16.15.1. Perinatal Use of Psychotropic Medications and Electroconvulsive Therapy
16.16. Physician Health and Wellness
16.17. Schizophrenia Spectrum and Other Psychotic Disorders
16.18. Suicide Risk Assessment
17. Respirology
17.1. Asthma
17.2. Bronchiectasis
17.3. Bronchiolitis Obliterans
17.4. Bronchitis, Acute
17.5. Chronic Obstructive Pulmonary Disease (COPD)
17.6. Cystic Fibrosis
17.7. Diphtheria
17.8. Interstitial Lung Diseases
17.8.1. Diffuse Alveolar Hemorrhage (DAH)
17.8.2. Eosinophilic Lung Diseases
17.8.3. Hypersensitivity Pneumonitis (HP)
17.8.4. Idiopathic Interstitial Pneumonias
17.8.4.1. Idiopathic Pulmonary Fibrosis (IPF)
17.8.4.2. Selected Other Types of Idiopathic Interstitial Pneumonia
17.8.5. Rare Interstitial Lung Diseases
17.8.6. Sarcoidosis
17.9. Larynx Diseases
17.9.1. Epiglottitis
17.9.2. Laryngeal Cancer
17.9.3. Laryngitis
17.9.4. Voice Disorders: Functional and Organic Dysphonia
17.10. Mediastinal Diseases
17.10.1. Mediastinal Cysts and Tumors
17.10.2. Mediastinitis
17.10.3. Pneumomediastinum
17.11. Neoplasms of the Lung and Pleura
17.11.1. Lung Cancer
17.11.2. Pleural Mesothelioma
17.11.3. Pulmonary Metastases
17.12. Nicotine Addiction
17.13. Occupational Respiratory Diseases
17.13.1. Berylliosis
17.13.2. Pneumoconiosis
17.13.3. Work-Related Asthma
17.14. Pertussis
17.15. Pharyngitis (Tonsillitis)
17.16. Pleural Diseases
17.16.1. Pleural Effusion
17.16.1.1. Chylothorax
17.16.1.2. Exudative Pleural Effusion
17.16.1.2.1. Exudative Pleural Effusion Caused by Malignancy
17.16.1.2.2. Exudative Pleural Effusion in the Course of Bacterial Pneumonia
17.16.1.3. Hemothorax
17.16.1.4. Transudative Pleural Effusion
17.16.2. Pneumothorax
17.17. Pneumonia
17.17.1. Community-Acquired Pneumonia (CAP)
17.17.2. Hospital-Acquired Pneumonia (HAP)
17.17.3. Pneumonia Caused by Specific Etiologic Agents
17.17.3.1. Influenza Pneumonia
17.17.3.2. Pneumonia Caused by Aspergillus spp (Invasive Aspergillosis)
17.17.3.3. Pneumonia Caused by Pneumocystis jiroveci (Pneumocystosis)
17.17.3.4. Pneumonia Caused by Other Pathogens
17.18. Pulmonary Hypertension (PH)
17.19. Respiratory Failure
17.19.1. Acute Respiratory Failure
17.19.1.1. Acute Respiratory Distress Syndrome (ARDS)
17.19.2. Chronic Respiratory Failure
17.20. Rhinosinusitis
17.21. Sleep-Related Breathing Disorders
17.21.1. Central Sleep Apnea (CSA)
17.21.2. Obstructive Sleep Apnea (OSA)
17.22. Tuberculosis (TB) and Other Mycobacterial Infections
17.22.1. Nontuberculous Mycobacterium Diseases
17.22.2. Tuberculosis: Active Disease
17.22.3. Tuberculosis: Latent Tuberculosis Infection (LTBI)
18. Rheumatology
18.1. Adult-Onset Still Disease (AOSD)
18.2. Algodystrophy (Complex Regional Pain Syndrome)
18.3. Amyloidosis
18.4. Antiphospholipid Syndrome
18.5. Back Pain Syndromes
18.6. Bone and Joint Dysplasias
18.7. Bursitis: General Considerations
18.8. Crystal-Mediated Diseases
18.8.1. Calcium Pyrophosphate Dihydrate Deposition (CPPD) Disease
18.8.2. Gout
18.9. Erythema Nodosum
18.10. Fibromyalgia
18.11. Infectious (Septic) Arthritis
18.12. Mixed Connective Tissue Disease (MCTD), Undifferentiated Connective Tissue Disease (UCTD), Overlap Syndromes
18.13. Osteoarthritis
18.14. Osteomalacia
18.15. Osteonecrosis
18.16. Osteoporosis
18.17. Paget Disease of Bone
18.18. Panniculitis
18.19. Polymyalgia Rheumatica (PMR)
18.20. Polymyositis and Dermatomyositis
18.21. Rheumatoid Arthritis (RA)
18.22. Sjögren Syndrome
18.23. Spondyloarthritides (SpAs)
18.23.1. Ankylosing Spondylitis
18.23.2. Enteropathic Arthritis
18.23.3. Psoriatic Arthritis
18.23.4. Reactive Arthritis
18.24. Systemic Lupus Erythematosus (SLE)
18.25. Systemic Sclerosis (SSc)
18.26. Vasculitis Syndromes
18.26.1. Anti–Glomerular Basement Membrane Disease (Formerly Goodpasture Syndrome)
18.26.2. Behçet Disease
18.26.3. Cryoglobulinemic Vasculitis
18.26.4. Cutaneous Leukocytoclastic Angiitis
18.26.5. Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)
18.26.6. Giant Cell Arteritis (GCA)
18.26.7. Granulomatosis with Polyangiitis
18.26.8. IgA Vasculitis (Henoch-Schönlein Purpura)
18.26.9. Microscopic Polyangiitis
18.26.10. Polyarteritis Nodosa
18.26.11. Takayasu Arteritis
19. Toxicology and Addiction
19.1. Approach to the Poisoned Patient
19.2. Acetaminophen (Paracetamol)
19.3. Alcohols
19.3.1. Ethyl Alcohol (Ethanol)
19.3.1.1. Acute Alcohol Withdrawal
19.3.2. Ethylene Glycol
19.3.3. Isopropyl Alcohol
19.3.4. Methyl Alcohol (Methanol)
19.4. Anticholinergic Syndrome (Anticholinergic Toxicity)
19.5. Benzodiazepines
19.6. Carbon Monoxide
19.7. Cholinergic Syndrome (Cholinergic Toxicity)
19.8. Digoxin and Other Cardiac Glycosides
19.9. Lithium Toxicity
19.10. Opioids
19.10.1. Acute Opioid Toxicity
19.10.2. Acute Opioid Withdrawal in the Emergency Department
19.10.3. Opioids and Opioid Use Disorder: General Considerations
20. Noninvasive Diagnostic Tests
20.1. Diagnostic Imaging
20.1.1. COVID-19: Computed Tomography (CT)
20.1.2. COVID-19: Point-of-Care Ultrasonography (POCUS)
20.2. Electrocardiography
20.2.1. Standard Electrocardiography
20.2.2. Holter Electrocardiography
20.2.3. Exercise Stress Testing
20.3. Pulse Oximetry
20.4. Laboratory Tests
20.4.1. Laboratory Tests: General Remarks
20.4.2. Biochemical, Hematologic, and Coagulation Tests
20.4.3. Cerebrospinal Fluid Analysis
20.4.4. Pericardial Fluid Analysis
20.4.5. Peritoneal Fluid Analysis
20.4.6. Pleural Fluid Analysis
20.4.7. Synovial Fluid Analysis
20.4.8. Urinalysis
21. Procedures
21.1. Abdominal Paracentesis
21.2. Arthrocentesis: Knee, Wrist, Ankle
21.3. Defibrillation
21.4. Electrical Cardioversion
21.5. Fiberoptic Endoscopic Examination of Swallowing (FEES)
21.6. Gastric Lavage
21.7. Infiltration Anesthesia
21.8. Injections of Drugs and Other Substances
21.8.1. Intramuscular Injections
21.8.2. Intravenous Injections
21.8.3. Subcutaneous Injections
21.9. Lumbar Puncture
21.10. Mechanical Circulatory Support (MCS)
21.10.1. Extracorporeal Membrane Oxygenation (ECMO)
21.10.2. Intra-Aortic Balloon Pump (IABP)
21.10.3. Total Artificial Heart (TAH)
21.10.4. Ventricular Assist Devices (VADs)
21.11. Nasogastric or Orogastric Tube Insertion
21.12. Pericardiocentesis
21.13. Pleural Drainage
21.14. Procedural Sedation and Analgesia
21.15. Respiratory Support
21.15.1. Invasive Mechanical Ventilation
21.15.2. Nasal High-Flow Therapy (NHFT)
21.15.3. Noninvasive Mechanical Ventilation and Continuous Positive Airway Pressure
21.15.4. Oxygen Therapy
21.16. Surgical Field Preparation for Small Procedures
21.17. Thoracentesis
21.18. Urethral Catheterization
21.19. Vascular Access and Catheterization
21.19.1. Blood Sample Collection for Blood Gas Analysis
21.19.1.1. Arterial Blood Gas Sampling
21.19.1.2. Arterialized Capillary Blood Sampling
21.19.2. Peripheral Venous Blood Sampling
21.19.3. Peripheral Venous Catheter Placement
21.20. Videofluoroscopic Swallowing Study (VFSS)
22. Trauma and Injuries
23. Epistaxis
24. Acute and Critical Medical Care
The only international review course in internal medicine from McMaster University, the home of evidence-based medicine (EBM) and one of the best medical schools in the world.
World class speakers and trainers
Our lineup of speakers includes world-renowned experts in their fields, authors of clinical practice guidelines, and researchers behind breakthrough trials that shape the modern standards in medicine. Coming from different universities and research centers, they are uniquely qualified to trace, explain, and address the emerging trends in medicine around the world, combining local experience with international standards.
Organized by
in cooperation with
Frequently asked questions
Who is this course intended for?
Can I join this course as a student?
Yes. This course is addressed to both physicians and students.
Will I receive a certificate after the course?
Yes. First we will ask you to complete an evaluation and feedback form. This will allow us to issue a PDF certificate with the number of CME credits obtained. You can claim up to 22 CME credits for the complete course. CME credits are available through November 11, 2024.
Do I need to register an account to sign up for the course?
Yes. You need to register an account to place and finalize your order in our Orders & Payments system.
I have a problem with registration and/or payment, who can help me?
In case of any problems with registration and/or payment, please contact Marta Pasiut at registration@piebm.org.
Will I receive an invoice?
Yes. The invoice will be sent automatically to your email address once we have received and processed your payment. It may take up to 3 working days.
Do I need to be present live to receive CME credits?
Can I convert/transfer my CME credits?
Yes. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Credit will be converted based on one (1) hour of participation equaling one credit for all activities. Physicians wishing to
convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.
For other countries, please contact the relevant national/regional accreditation authority.
How can I log in to the virtual platform?
I am not sure what my login credentials are, how can I check them?
I don’t remember my password, can I recover it?
How can I access the McMaster Texbook of Internal Medicine?
Shortly after your purchase, you will receive an onboarding email with instructions on how to redeem your access to the McMaster Textbook of Internal Medicine. The offer includes access to the online (web-based) version as well as mobile apps. The login credentials (username and password) are the same as for accessing the MIRCIM 2024 Virtual Platform.
How long will I have online access to the course?
You will receive one-year on-demand access to the virtual course. In the first 6 months, from May 12 till November 12, 2024, you can earn and claim your CME credits for watching the video recordings. After November 12, 2024, you can still watch the videos but no longer receive the CME credits.
What is the Best Case Report Contest?
Best Case Report Contest is a contest where junior internists and trainees in internal medicine from around the world educate one another using examples from their own practice.
It is addressed to internal medicine specialists or trainees in internal medicine up to 35 years of age representing national societies of internal medicine or universities who are the official partners of the McMaster International Review Course in Internal Medicine (MIRCIM).
The 20 top-ranked case reports from around the world are presented by the authors and discussed by world-renowned experts during the session Clinical Cases in Internal Medicine: Learning Through Practice.
The other case reports, which are not qualified for oral presentations, are presented by the authors at poster sessions to the on-site audience and experts, and in a digital form (abstracts and e-posters) to the virtual audience.
If you need any further assistance...
...talk directly to Marta, our Conference Manager!
Marta Pasiut
registration@piebm.org
+ 48 663 430 239 (mobile and WhatsApp)
Working hours
Mon 12-18 | Tue 9-17 | Wed 12-18 | Thu 9-17 | Fri 9-17
Central European Summer Time / UTC+2
Polish Institute for Evidence Based Medicine
Gazowa 14A | 31-060 Kraków, Poland
contact@piebm.org | www.piebm.org
This is the heading
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.